Pulmonary embolism: ‘the great masquerader’ of pneumonia in a patient with progressive supranuclear palsy
Robin G. Manappallil, Vinod Krishnan

Department of Medicine, National Hospital, Calicut, Kerala, India
Correspondence to Dr. Robin George
Manappallil, MBBS, MD (Internal Medicine), Department of Medicine, National Hospital, Calicut, 673001 Kerala, India
Tel : 00918554775339; fax : 00914952372400; e-mail: drrobingeorgemep@gmail.com
Received 31 August 2015
Accepted 30 September 2015
The Egyptian Society of Internal Medicine 2016, 28:30–32

Introduction
Progressive supranuclear palsy (PSP) is an idiopathic neurodegenerative disorder characterized by akinetic rigid Parkinsonism, unsteadiness, dizziness, slowness, falls and pseudobulbar dysarthria. It is sporadic in nature [1]. This unusual syndrome was first described by John Clifford Richardson in 1963, along with John Steele and Jerzy Olszewski, which eventually led to the naming of this syndrome as Steele–Richardson–Olszewski syndrome [2].

Previous studies have suggested that patients with Parkinson’s disease could possibly be at risk for developing deep vein thrombosis (DVT) and pulmonary embolism (PE). This case report attempts to explain that patients with PSP are also at risk of developing PE and how PE may mimic pneumonia in such patients.

Case history
Our patient is a 68-year-old man, a retired office worker, with a medical history of PSP who is on synpoda 110 mg (levodopa 100+carbidopa 10 mg) for the past 4 months. He presented to the Emergency Department with a history of fever, mild cough with scanty white expectoration and dyspnea of 1-day duration. He had no other local or systemic complaints. He was treated for left lower lobe pneumonia with intravenous antibiotics 1 month ago. The patient was also a hypertensive on regular medications (losartan and amlodipine).

On examination, the patient was conscious and oriented. His vitals showed a heart rate of 120 beats/min, blood pressure of 90/60 mmHg, temperature of 100°F and respiratory rate of 32 breaths/min with 88% oxygen saturation in room air. Neurological examination indicated bradykinesia, tremors and slurred monotonous speech. The motor system showed cogwheel rigidity and cranial nerve examination indicated defective downward gaze. His respiratory system examination showed fine crepitations over the right infrascapular region. No cardiovascular or abdominal abnormalities were noted. On the basis of the history and clinical findings, an initial diagnosis of right-sided pneumonia with hypotension was made.

However, his ECG showed the presence of the S wave in lead I, and an inverted T wave in III and V1–V4 (Fig. 1). His troponin I was weakly positive. Chest radiography showed features suggestive of right-sided PE, that is, wedge-shaped opacity, enlarged pulmonary artery, horizontal linear opacities in the lower zone and oligemia of the lung field (Fig. 2). Echocardiogram showed dilatation of the right atrium and ventricle, with mild tricuspid regurgitation and mild pulmonary artery hypertension. Arterial blood gas reported a pH of 7.49, and pO2 and pCO2 of 58 and 23 mmHg, respectively. His d-dimer value was elevated (1439 ng/ml). Computed tomography of the chest with intravenous contrast showed submassive embolism of the right and left pulmonary arteries (Figs. 3 and 4). Doppler ultrasound of the bilateral lower limbs did not show any evidence of DVT. His complete blood count, liver, renal and metabolic parameters did not show any abnormalities. His sputum culture showed mild growth of Moraxella catarrhalis. Other blood investigations such as protein C and S, homocysteine
levels, antinuclear antibodies and antiphospholipid antibodies were normal.

The patient was started on a weight-based dose of subcutaneous fondaparinux once daily for bridging over to warfarin, which was started at an evening dose of 5 mg. He was also administered levofloxacin as per sputum culture and sensitivity. Following 2 days of therapy, the patient improved symptomatically. He was discharged once the target international normalized ratio (INR) of 2 was achieved.

As this was a case of unprovoked PE, warfarin was continued for life and a target INR between 2 and 3 was maintained. The patient has been attending regular follow-up for his INR values. He was also asked to stop the drug syndopa.

Discussion

PSP is not a rare disease. The estimated annual incidence is about 0.3–1.1 cases per 100 000 persons [3]. It affects both sexes, with a slight male
preponderance. Genetically, these patients frequently show the H1 halotype and the H1/H1 genotype [4]. It is characterized by hyperphosphorylated tau protein aggregates. Macroscopic examination of the brain shows midbrain atrophy and substantia nigra depigmentation, sometimes with mild frontal lobe atrophy, whereas microscopic examination shows neuronal loss, gliosis, neurofibrillary tangles and neuropil threads in the basal ganglia and brainstem [5]. The onset is typically in the sixth decade (range 45 to 75 years) [6]. Clinically, vertical gaze palsy, axial rigidity, pseudobulbar palsy and cognitive impairment have been described as the hallmarks of PSP [7]. Since 1964, a history of fall within the first year of illness has also been included in the criteria [8]. The most common early symptom is an unsteady gait and unexplained falling without loss of consciousness. There is no gait ataxia, but patients tend to lean and fall backward. There is also gradual stiffening and extension of the neck. The patient's face acquires a staring, worried look with a furrowed brow. The face becomes less expressive, speech is slurred, the mouth tends to be held open and swallowing becomes difficult. Many patients may complain of sleep disturbances [6].

PSP becomes progressively worse, but is not directly life-threatening in itself. The most common complications are pneumonia, head injury and fractures caused by falls. There is currently no effective treatment for PSP. In some individuals, the slowness, stiffness and balance problems of PSP may respond to anti-Parkinsonism agents such as levodopa, but the effect is usually temporary. Zolpidem has been found to ameliorate bradykinesia and rigidity. Weighted walking aids have been used to prevent a backward fall. Special glasses called prisms are sometimes prescribed as a remedy for the difficulty in looking down. A gastrostomy may be necessary to tackle swallowing disturbances. Autologous adipose tissue-derived mesenchymal stem cell transplantation show promising results in delaying the progression of PSP [9].

Venous thromboembolism includes DVT and PE. The common predisposing factors include cancer, hypertension, obesity, cigarette smoking, chronic obstructive pulmonary disease, long-haul air travel, oral contraceptive pills, pregnancy, postmenopausal hormone replacement, surgery and trauma. Deficiencies of protein C and S and antithrombin, hyperhomocysteinaemia and antiphospholipid antibody syndrome are some of the rare causes [10]. Postural abnormalities have been reported as a risk factor for DVT in patients with Parkinson's disease [11]. PE may also develop as an adverse reaction to levodopa therapy [12].

Patients with PSP are at risk of thrombosis probably because of decreased mobility secondary to Parkinsonism or as an adverse effect of levodopa. Aspiration pneumonia is a common complication of PSP. This case emphasizes the fact that patients with PSP are also prone to unprovoked PE and how this complication may mimick pneumonia.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1 Mahon RD, Jorge LJ. Parkinson’s disease and other extrapyramidal movement disorders. Harrison’s principles of internal medicine. In: Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. 17th edition 2008; 2:2559.
2 Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical supranuclear gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10:333–351.
3 Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49:1284–1288.
4 Bennett P, Bonifati V, Bonuccelli U, Colosimo C, De Mari M, Fabbriini G, et al. Direct genetic evidence for involvement of tau in progressive supranuclear palsy. European Study Group on Atypical Parkinsonism Consortium. Neurology 1998; 51:982–985.
5 Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, et al. Preliminary NINDS neuropathologic criteria for Steele–Richardson–Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44:2015–2019.
6 Alan HR, Martin AS. Degenerative diseases of nervous system. Adams and Victor’s principles of neurology. In: Sydor AM, Davis KJ, eds. 9th edition 2009; 39:1046–1048.
7 Duvoisin RC. Clinical diagnosis. In: Litvan I, Agid Y, eds. Progressive supranuclear palsy: clinical and research approaches. New York: Oxford University Press; 1992. 15–33.
8 Lubarsky M, Juncos JL. Progressive supranuclear palsy: a current review. Neurology 2008; 14:79–88.
9 Choi SW, Park KB, Woo SK, Kang SK, Ra JC. Treatment of progressive supranuclear palsy with autologous adipose tissue-derived mesenchymal stem cells: a case report. J Med Case Reports 2014; 8:87.
10 Samuel ZG. Deep venous thrombosis and pulmonary thromboembolism. Harrison’s principles of internal medicine. In: Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. 17th edition 2008; 2:2170–2177.
11 Yamane K, Kimura F, Unoda K, Hosokawa T, Hirose T, Tani H, et al. Postural abnormality as a risk marker for leg deep venous thrombosis in Parkinson’s disease. PloS One 2013; 8:e66984.
12 Hung SC, Tai CT. Parkinson’s disease with recurrent pulmonary embolism. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63:487–491.